Skip to content
StockMarketAgent
Direct answer
Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow. Fair value range: low $109, high $170, with mid-point at $140.
Stock analysis

ZTS ZTS fair value $109–$170

ZTS
By StockMarketAgent.AI team· supervised by
Analyzed: 2026-05-12Next update: 2026-08-12Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
Last price
$76.94
▲ +62.83 (+81.66%)
Fair value
$140
$109–$170
Rating
Strong Buy
confidence 88/100
Upside
+81.7%
upside to fair value
Margin of Safety
$118.80
MoS level · 15%
Market Cap
$32.3B
P/E fwd 10.3

§1 Executive summary

  • Composite fair value $140 with high case $170.
  • Implied upside of 81.7% to fair value.
  • Moat 9/10 · confidence 88/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$140
Margin of safety
+45.0%
Confidence
88/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$76.94Price
Low $109.15
Mid $139.77
High $170.49

Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growthRevenue growthYear-over-year change in revenue, expressed as a percentage. The starting point for any forward-earnings model and the lens through which scale, mix, and pricing power become visible. and high operating margins (~37%), it generates strong and predictable free cash flowFree cash flowOperating cash flow minus capital expenditures. The cash a business generates after maintaining and growing its asset base — the closest accounting proxy for owner-economics..

  • Intangible assets via unmatched patent
    Intangible assets via unmatched patent portfolio and brand loyalty.
  • High switching costs for veterinary
    High switching costs for veterinary practitioners integrated into the Zoetis ecosystem.
  • Cycle upside
    Accelerating pet humanization driving inelastic, premium companion animal healthcare spending.

§2 Bear case

A macroeconomic shock compressing discretionary pet spending combined with a cyclical livestock downturn would threaten historical 37% operating margins. The reverse DCFReverse DCFInverts a standard DCF: instead of solving for fair value, we solve for the growth rate the current price already implies — a useful test of whether the market's assumptions are reasonable. implies the market is already pricing in a structural decay (-2.52% perpetual growth), providing a massive margin of safetyMargin of safetyThe discount required between fair value and current price before we recommend buying. Typically 15% for wide-moat names, 25–35% for cyclicals or low-confidence cases. against such cyclical shocks.

Ways this thesis can break

Margin Contraction

· Low

Operating margins sustainably drop below 35% due to generic competition and loss of pricing power.

FV impact
Valuation compresses to the $109.15 low-end threshold.

Livestock Headwinds

· Medium

Prolonged livestock disease cycle reduces the agricultural segment revenues structurally, dragging corporate growth.

FV impact
Mild drag on terminal value generation and forward EPS.

Macro Demand Shock

· Medium

Deep recession forces broad reduction in discretionary companion animal treatments and veterinary visits.

FV impact
Near-term EPS shock testing the $110 forward earnings scenario value.
Early-warning signals to monitor
MetricCurrentTrigger threshold
Operating margin contracting below 35% over two consecutive quarters.MonitorDeterioration versus the report thesis
Forward EPS growth turning negative.MonitorDeterioration versus the report thesis
ROIC dropping precipitously toward the 8.43% WACC.MonitorDeterioration versus the report thesis
Erosion of the 71.8% gross margin floor.MonitorDeterioration versus the report thesis
Accelerated generic approvals targeting core parasiticide or dermatology portfolios.MonitorDeterioration versus the report thesis

§3 Financial history

Income statement — last six periods
Line itemT−0T−1T−2T−3CAGR
Period2022-12-312023-12-312024-12-312025-12-31Trend
Revenue$8.08B$8.54B$9.26B$9.47B+5.4%
Gross profit$5.63B$5.98B$6.54B$6.80B+6.5%
Operating income$2.93B$3.07B$3.39B$3.60B+7.1%
Net income$2.11B$2.34B$2.49B$2.67B+8.1%
EPS (diluted)$4.49$5.07$5.47$6.02+10.3%
EBITDA$3.34B$3.67B$3.86B$4.07B+6.8%
R&D$539.0M$614.0M$686.0M$698.0M+9.0%
SG&A$2.01B$2.15B$2.32B$2.38B+5.8%

Quality scores

OCF / Net income
1.09×
>1 indicates high earnings quality
Accounting quality gate
Fail
Sector-adjusted gate
ROIC
22.5%
Return on invested capital
§3

Numbers analysis

Cash flow

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Capital allocation

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Individual subscribers — §4 onwards11 more sections

Read the full analysis — 11 more sections.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Full report for every covered ticker
24 months of rating archive
Watchlist briefings + rating-change alerts
PDF + DOCX export in any language
Start free trial
Cancel anytime.
FAQ

ZTS — frequently asked questions

  1. Based on our latest analysis, ZTS looks meaningfully undervalued. The current price is $76.9 versus a composite fair-value midpoint of $140 (range $109–$170), which implies roughly 81.7% upside to the midpoint.
Related coverage

Names readers of ZTS also follow

Same archetype: mature-compounder